Sep 8, 2021 PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
Aug 31, 2021 PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study
Aug 25, 2021 PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise
Aug 23, 2021 PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Aug 19, 2021 PharmaCyte Biotech Announces $70 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Aug 9, 2021 PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering
Aug 2, 2021 PharmaCyte Biotech Announces Uplist to The Nasdaq Capital Market and Launch of Public Offering
